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A B S T R A C T
Bone marrow (BM) is an essential source of hematopoietic stem cell grafts for many allogeneic hematopoietic cell
transplant (HCT) recipients, including adult patients (for speciﬁc diseases and transplantation strategies) and the
majority of pediatric recipient. However, since the advent of granulocyte colony-stimulating factor-mobilized
peripheral blood stem cell (PBSC) grafts, there has been a signiﬁcant decrease in the use of BM in HCT, thought to
be due mainly to the increased logistical challenges in harvesting BM compared with PBSCs, as well as generally
no signiﬁcant survival advantage of BM over PBSCs. The decreased frequency of collection has the potential to
impact the quality of BM harvests. In this study, we examined >15,000 BM donations collected at National Marrow Donor Program centers between 1994 and 2016 and found a signiﬁcant decline in the quality of BM products,
as deﬁned by the concentration of total nucleated cells (TNCs). The mean TNC concentration in BM donations
dropped from 21.8 £ 106 cells/mL in the earliest era (1994 to 1996) to 18.7 £ 106 cells/mL in the most recent era
(2012 to 2016) (means ratio, .83; P < .001). This decline in BM quality was seen despite the selection of more
donors perceived to be optimal (eg, younger and male). Multivariate regression analysis showed that highervolume centers (performing >30 collections per era) had better-quality harvests with higher concentrations of
TNCs collected. In conclusion, we have identiﬁed a signiﬁcant decrease in the quality of BM collections over time,
and lower-volume collection centers had poorer-quality harvests. In this analysis, we could not elucidate the
direct cause for this ﬁnding, suggesting the need for further studies to investigate the key factors responsible and
to explore the impact on transplant recipients.
© 2019 American Society for Blood and Marrow Transplantation.

INTRODUCTION
Bone marrow (BM) is the original, and an essential, hematopoietic stem cell (HSC) source for many allogeneic hematopoietic
cell transplantation (HCT) recipients. However, with the advent
of granulocyte colony-stimulating factor-mobilized peripheral
blood stem cell (PBSC) transplants, and given the logistical advantages of PBSC collection over BM collection, signiﬁcant decreases
in the use of BM have occurred at many transplantation centers.
Since the introduction of PBSCs, the use of BM as the HSC source
in the unrelated donor setting has declined from 100% in the
early 1990s to 19% in 2017 [1]. Nonetheless, BM remains the preferred cell source for speciﬁc disease indications in adults (eg,
aplastic anemia), for the majority of pediatric transplants, and
when the beneﬁts of a decreased risk of chronic graft-versushost disease (GVHD) outweigh other considerations [24].
Indeed, several studies have demonstrated that recipients of BM
grafts experience less chronic GVHD than recipients of PBSC
grafts [2,5,6]. In addition, other studies have shown that pediatric
patients receiving BM have a survival advantage over patients
receiving PBSCs [3,7,8]. The recent use of HLA-mismatched and
haploidentical transplants at some centers and in current clinical
trials has also led to an increased use of BM in these settings,
owing to a presumed increased risk of GVHD overall with these
transplants [9,10].
The decreased use of BM in allogeneic HCT has several
potential consequences, including negatively affecting the
overall quality of BM donations owing to a lack of experience
with the harvesting procedure at both center and operator levels. Although standard operating procedures are in place and
centers provide initial training, ongoing competency assessment is often difﬁcult when few procedures are performed per
year in many centers. The Foundation for Accreditation of Cellular Therapies (FACT) standard requires the BM harvest team
of an accredited facility to perform at least 1 BM harvest per
year average in the accreditation cycle (ie, a minimum of 3 BM
harvests in the accreditation cycle of 3 years), to perform quality assessment of collection procedures, and to implement
standardized protocols [11]. However, FACT standards do not
address individual collector experience, a minimum number of
collections per individual collector per year, speciﬁc staff training, and collection techniques. In addition, proper assessment
of BM harvest metrics, including total nucleated cell (TNC)
dose collected compared with target dose, quality of BM collected, and adverse reactions in donors following collection, is

difﬁcult in an individual collection center when limited procedures are performed, and comparable evaluations from other
centers are not easily obtained.
In a single-center study, quality measurements found
decreasing TNC doses over time in BM products collected
externally and received for individual patients (personal communication, N. Prokopishyn, Jan 2008). We sought to conﬁrm
and explore potential reasons for this observation in a validation cohort. Thus, the aim of this study was to examine the
trends in BM harvest quality in a large cohort of National Marrow Donor Program (NMDP) donors over several decades to
establish whether this single-center observation could be generalized. To this end, we assessed the BM quality (deﬁned as
concentration of TNC per BM volume collected) in harvests
performed by NMDP centers between 1994 and 2016. In addition to the number of harvests per center per era, other donor
and procedure factors were examined to evaluate their impact
on BM quality.
METHODS
Study Population
The study population comprised domestic unrelated ﬁrst-time BM
donors of products collected at NMDP centers between 1994 and 2016. Data
on donor and donation characteristics were recorded on standard data forms
by the NMDP. All donors included in this study provided written informed
consent for participation in Center for International Blood and Marrow Transplant Research (CIBMTR) studies that were approved by the NMDP’s Institutional Review Board.
BM Donation
BM was collected in an operating room from the posterior iliac crests
under general or regional anesthesia in accordance with NMDP standards.
NMDP standards mandate aspiration of no more than 20 mL/kg (donor
weight) of marrow, a duration of anesthesia not to exceed 150 minutes, and a
duration of collection <120 minutes [12].
Data Collection
All data used in our analysis were reported by collection centers to the
NMDP/CIBMTR at the time of collection/transplantation. The number of collections per center per era was calculated using the number of collections
reported to the NMDP in this population.
Endpoints
The primary study outcome was the measurement of TNCs collected per
milliliter of BM as an estimate of HSC product quality. For each harvest, this
was calculated based on TNCs in the product and the volume of the ﬁnal
product, including additives. The calculation was performed before any processing at the transplantation center. The number of collections performed per
harvest center and era was also determined.
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Statistical Methods
The study population was analyzed over 5 eras: 1994 to 1996, 1997 to
2001, 2002 to 2006, 2007 to 2011, and 2012 to 2016. Eras were selected to
represent 5 years per period, except for the ﬁrst era, which covers only 3
years, 1994 to 1996, because before 1994, insufﬁcient data were available for
analysis. A variety of donor characteristics, including sex, age, and body mass
index (BMI), as well as collection volume with and without additives per
donor weight, were compared between eras using the chi-square test. Donor
weight, duration of anesthesia, duration of the collection procedure, product
volume with additive, and TNC concentration in the BM product were compared using the Kruskal-Wallis test. Collection centers were subdivided based
on collection center volume per harvest center per era. High-volume centers
were deﬁned as centers collecting 30 BM products per center per era; lowvolume centers, as those collecting <30 BM products per center per era.
For multivariate analysis, log transformation was applied to TNC concentrations to induce normality. Multiple linear regression was used to model
log TNC concentrations as a function of the primary variable of interest (era
of donation), as well as donor characteristics (ie, sex, race, age, and weight)
and the number of donations per harvest center per era. Stepwise variable
selection was used to select variables in addition to the primary variable of
interest. Interactions between the primary variable of interest and the other
covariates were assessed. Effects are summarized as ratios of means of the
TNC concentrations, owing to the use of log transformation for modeling. We
also investigated accounting for potential harvest center effects through
the use of linear mixed models, including a random effect for harvest center;
however, we found no signiﬁcant center effect, and the results were not
meaningfully impacted by adjusting for random center effects, and so those
results were omitted from our analysis.

RESULTS
More than 15,000 BM donations collected between 1994
and 2016 were examined in this study. Donor, collection, and
product data are provided in Table 1. We found a signiﬁcant
decline in the mean concentration of TNCs in the BM products
over time, from 21.8 £ 106 TNCs/mL in the earliest era (1994 to
1996) to 18.7 £ 106 TNCs/mL in the most recent era (2012 to
2016) (means ratio, .83; P < .001) (Table 2 and Figure 1).
In recent eras, BM donors were signiﬁcantly more likely to
be young (P < .001) and male (P < .001) (Table 1). In the 2012
to 2016 era, 54% of the donors were age <30, compared with
only 25% in 1994 to 1996 and 1997 to 2001. Similarly, 65% of
the donors were male in the 2012 to 2016 era, compared with
53% in 1994 to 1996 era. Moreover, there was a signiﬁcant difference in donor weight over time, with donors in the 2012 to
2016 era weighing more than donors in earlier eras (Figure 2).
Univariate analysis of recipient weight found signiﬁcant differences over time as well (Figure 3).
The number of centers performing collections varied from a
high of 106 centers in the 1997 to 2001 era to a low of 73 centers in the most recent era examined, 2012 to 2016 (Table 1).
Similarly, the highest number of total BM collections was
recorded in the 1997 to 2001 era. However, the mean number
of collections per center was highest in the 2012 to 2016 era.
The average number of collections per era increased over the
last 3 eras (Table 1) even though the number of collection centers performing BM harvests declined.
Multivariate analysis conﬁrmed the impact of era on reduced
BM quality over time, with a ratio of means TNC concentration
of .83 in 2012 to 2016 compared with 1994 to 1996 (95% conﬁdence interval [CI], .81 to .84; P < .001) (Table 3). Donor race
was also found to be associated with a reduction in BM quality
over time, with signiﬁcantly lower TNC doses in Hispanic, African/African American, and Asian Paciﬁc Islander donors compared with Caucasian donors (mean ratio, .98 [95% CI, .96 to .99],
.85 [95% CI, .84 to .87], and .90 [95% CI, .88 to .92], respectively).
Older donors had lower BM quality with compared to the youngest donors (age 18 to 29 years). Donor factors associated with
increased BM quality included female sex (mean ratio compared
with male donors, 1.04; 95% CI, 1.03 to 1.06), and donor weight,
with better quality in heavier donors. The heaviest donor group,
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weighing >83 kg, had a mean ratio of 1.14 compared with the
lightest donors weighing 69 kg (95% CI, 1.12 to 1.16). The number of BM collections at a center per era was also associated with
BM quality, with centers performing 30 collections per era having a signiﬁcantly better correlation with BM quality compared
with centers performing <30 collections per era (mean ratio,
1.02; 95% CI, 1.01 to 1.04) (Table 3, Figure 4).
DISCUSSION
In this large study of unrelated BM donor harvests, we found a
signiﬁcant decrease in the quality of BM products over time, as
demonstrated by a drop in the TNC dose collected in recent years.
Interestingly, these results were found despite the increased use
of what are considered optimal donors (eg, younger males) in
more recent eras [1316]. The use of younger male donors has
been linked to higher TNC doses in BM products in some studies
[14,16]; however, this was not found in our study, in which lower
BM quality was associated with male sex. Older age and all other
races except Caucasian and Native American were associated
with lower TNC doses collected. Although there was a change in
racial diversity of the donor population over time, with a reduction from 81% Caucasian in the earliest era to 61% Caucasian
in the most recent era, racial diversity is not likely responsible for
the decreasing TNC doses over time, given that even with adjustments for race in the multivariate model, the effect remained signiﬁcant. Donor weight >69 kg was associated with higher BM
quality. Interestingly, we noted an increase in donor weight in
the recent era. However, this increase in donor weight and its
purported positive effects on BM quality did not prevent the signiﬁcant decline in BM quality in the current era. As such, shifts in
donor types used in BM collection today do not explain the
observed decline in TNC concentration. Unfortunately, approximately 34% of donors did not have an associated recipient weight
reported, and thus no conclusions could be drawn regarding the
impact of time on the TNC dose collected per kilogram of recipient weight. The reduction in recipient weight seen in the later
eras may be a result of an increased proportion of the BM products used in pediatric recipients.
Multivariate analysis showed that volume of collection center BM harvests may play a crucial role in BM quality, as we
found that higher-volume collection centers collected higherquality BM products. Speciﬁcally, collection centers that collect
30 BM products per era collect higher-quality products than
those centers collecting <30 BM products per era (Figure 4).
Therefore, factors such as collector experience, collection center policies and procedures, collection team training/continuing competency, and collection technique may play signiﬁcant
roles. Indeed, Fagioli et al [17] spoke to the importance of collector training and standardized procedures in the quality of
BM harvested. In low-volume centers, the number of harvests
performed per collector may be insufﬁcient to maintain the
appropriate level of expertise in BM procedures.
In addition, speciﬁc technical aspects of the BM collection,
which differ from center to center, may have a profound inﬂuence on the TNC concentrations collected. For example, the
speed of the collection and harvest draws can impact the concentration collected, with faster collections yielding lower TNC
concentrations [14,18]. The speed of collection can be inﬂuenced both by harvester technique and the type of needle used
in the collection [18,19]. In addition, some studies have suggested that large-volume collections and longer collection
times can decrease the likelihood of obtaining the desired TNC
dose [20,21]. Furthermore, larger aspirate volumes have been
shown to produce decreased TNC and CD34+ cell counts compared with smaller aspirate volumes [20,22,23]. Indeed,
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Table 1
Donor, Collection, and Product Data by Era
Variable

1994-1996

Number of donors
1720
Number of centers
90
Sex, n (%)
Female
806 (47)
Male
914 (53)
Race, n (%)
Caucasian
1400 (81)
Hispanic
109 (6)
African/African American
94 (5)
Asian/Paciﬁc Islander
63 (4)
Native American
19 (1)
Multiple/other
19 (1)
Unknown/declined
16 (1)
Age at donation, yr
18-29, n (%)
424 (25)
30-39, n (%)
640 (37)
40-49, n (%)
514 (30)
50+, n (%)
142 (8)
Median (range)
37 (19-58)
Weight, kg
Number evaluated
1720
Median (range)
76 (26-175)
Collection-related variables
Duration of anesthesia, min
Number evaluated
0
Median (range)
(.-.)
Duration of collection, min
Number evaluated
0
Median (range)
(.-.)
Product-related variables
Collection volume, without additives, L
<1, n (%)
0
1-1.5, n (%)
0
1.5, n (%)
0
Unknown, n (%)
1720 (N/A)
Median (range)
(.-.)
Collection volume with additive
per donor weight, mL/kg
<10
0
10-<15
0
15-<20
0
20
0
Unknown
1720 (N/A)
Median (range)
(.-.)
Product volume, with additive, mL
Number evaluated
1718
Median (range)
1200 (91-2782)

1997-2001

2002-2006

2007-2011

2012-2016*

4439
106

3135
91

2999
80

3583
73

P Valuey

<.001
2026 (46)
2413 (54)

1263 (40)
1872 (60)

1164 (39)
1835 (61)

1267 (35)
2316 (65)

3235 (73)
472 (11)
294 (7)
240 (5)
74 (2)
94 (2)
30 (1)

2318 (74)
291 (9)
200 (6)
134 (4)
48 (2)
121 (4)
23 (1)

1999 (67)
357 (12)
194 (6)
181 (6)
36 (1)
210 (7)
22 (1)

2174 (61)
516 (14)
270 (8)
215 (6)
28 (1)
352 (10)
28 (1)

1089 (25)
1600 (36)
1357 (31)
393 (9)
37 (19-61)

927 (30)
1060 (34)
867 (28)
281 (9)
36 (19-61)

1175 (39)
917 (31)
690 (23)
217 (7)
33 (19-61)

1946 (54)
939 (26)
519 (14)
179 (5)
29 (19-60)

<.001

<.001

<.001

4439
79 (9-200)

3135
82 (14-193)

2999
82 (40-164)

3583
81 (41-150)

<.001

0
(.-.)

1546
90 (26-248)

2987
92 (25-355)

1682
88 (34-301)

.042

0
(.-.)

1559
55 (7-194)

2989
51 (2-208)

1686
48 (0-221)

0
0
0
4439 (N/A)
(.-.)

689 (44)
695 (44)
181 (12)
1570 (N/A)
1064 (68-2360)

1302 (44)
1304 (44)
370 (12)
23 (N/A)
1067 (119-2323)

1490 (42)
1424 (40)
606 (17)
63 (N/A)
1090 (125-2214)

0
0
0
0
4439 (N/A)
(.-.)

482 (31)
490 (31)
519 (33)
74 (5)
1570 (N/A)
13.1 (.7-23.6)

4424
1257 (180-3110)

3127
1266 (128-2767)

<.001
<.001

898 (30)
984 (33)
904 (30)
190 (6)
23 (N/A)
13.1 (1.2-29.0)
2993
1246 (139-2557)

<.001
<.001

1029 (29)
1033 (29)
1087 (31)
371 (11)
63 (N/A)
13.6 (1.3-40.2)

<.001

3550
1290 (108-2720)

<.001

N/A indicates not applicable.

Helgestad et al [24] reported that small-volume marrow aspirates provide more representative BM results with less blood
contamination. Interestingly, our data show that the volume of
BM collected increased while the duration of the harvest
decreased in the latest era. Previous studies have indicated
that larger product volumes are being collected in short time
periods, most likely to obtain the requested cell dose for recipients [25]. Although a shorter collection time is beneﬁcial and
associated with reduced adverse reactions in donors [26], it

may negatively affect the product quality [27], [28]suggesting
that a compromise between these extremes may be optimal.
Whether the decreased TNC concentrations observed in our
study were the result of larger aspirates obtained during harvesting is unknown, given that aspirate volume and speed of
draw were not reported. Moreover, the type of needle used for
BM collection was not reported, and thus it is impossible to
determine the inﬂuence of harvesting equipment and supplies
on our ﬁndings.

Table 2
Concentration of TNCs with Additive over Time
Variable

1994- 1996

Number of donors
1720
Number of centers
90
Concentration of TNCs with
additive, £ 106/mL
Number evaluated
1718
Median (range)
21.8 (4.3-3450.0)

1997- 2001

2002- 2006

2007- 2011

2012-2016

4439
106

3135
91

2999
80

3583
73

4420
20.3 (4.3-2400.0)

3121
19.8 (.3-1320.0)

2989
19.5 (3.1-16,236.7)

3547
18.7 (1.2-349.8)

P Value

<.001
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Figure 1. Median concentration of TNCs with additive, £ 106 cells/mL, by era
of collection and collection center size.

Figure 4. Number of collections per year by era, with mean (x) and median
(^) values. The maximum number of collections performed per year in the
era is represented numerically, with the box representing the 25th and 75th
percentiles. The arrows indicate the maximum number of collections per era,
which are >60 (230 for 1994-1996, 477 for 1997-2001, 479 for 2007-2011,
and 920 for 2012-2016) and are not represented, to more accurately depict
the difference in quartile values across eras.
Table 3
Multivariate Model Using Linear Regression on Log TNC Concentration
Variable

Figure 2. Donor weight increased signiﬁcantly over time (P < .001). Data are
for the 1st percentile, lower quartile, median, upper quartile, and 99th percentile by examined eras.

Figure 3. Reduction in weight of BM recipients over time. Data are median,
with 1st percentile, lower quartile, upper quartile, and 99th percentile.
N = 10,437; associated recipient weight data were available for only 66% of the
donors.

Furthermore, details regarding collector experience, technique, training, and staff turnover were not available. Further
studies examining the collection process, including training,
techniques, equipment, and donor characteristics, will help
elucidate the entire process and aid the identiﬁcation of strategies aimed at improving the quality of BM products collected.
For example, examination of the role of educational tools, such
as the NMDP’s BM collection video, and their impact on technique standardization would be beneﬁcial to determine
whether speciﬁc variables can help improve BM quality. In
addition, the consolidation of BM harvests into centralized
“super centers” may affect many of these variables and address
several concerns, although such super centers might not be
feasible in many settings. Interestingly, the number of centers
performing BM harvests has decreased by more than 30% since

Collection year
1994-1996
1997-2001
2002-2006
2007-2011
2012-2016
Donor race
Caucasian
Hispanic
African/African American
Asian Paciﬁc Islander
Native American
Multiple race/other
Unknown/declined
to answer
Donor sex
Male
Female
Number of collections
per center
<30
30
Donor age at collection
18-29
30-39
40-49
50+
Donor weight, kg
69
69-71
71-83
83+

95% CI

P Value

1.00
.92
.89
.87
.83

.90-.93
.87-.90
.86-.89
.81-.84

<.001
<.001
<.001
<.001
<.001

1.00
.98
.85
.90
1.04
.97
.92

<.001
.96-.99
.003
.84-.87
<.001
.88-.92
<.001
.99-1.09
.083
.95-.99
.014
.87-.97
.003

1.00
1.04

<.001
1.03-1.06 <.001

1.00
1.02

<.001
1.01-1.04 <.001

Relative Effect (Relative
Change in TNC
Concentration)

1.00
.98
.92
.89
1.00
1.04
1.07
1.14

.97-.99
.91-.93
.87-.91

<.001
<.001
<.001
<.001

<.001
1.01-1.07
.004
1.05-1.09 <.001
1.12-1.16 <.001

the peak of 106 centers in 1997 to 2001 (Table 1). However, it
is unknown how many of the collections were performed by
these centers that no longer perform collections.
In conclusion, we found that the quality of BM harvests has
decreased over time, and that collection centers performing
smaller numbers of BM harvests per year collect lower-quality

1330

N.L. Prokopishyn et al. / Biol Blood Marrow Transplant 25 (2019) 13251330

BM products. This decline in BM quality has persisted even
though centers have been using more optimal donors in recent
eras. Further studies are needed to elucidate the factors
responsible for this signiﬁcant decrease in BM quality and, critically, to determine the impact of this declining BM quality on
transplantation outcomes, to ensure that BM remains a highquality source of HSCs for HCT.
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